TrialGynecologic oncology2022

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.

Carol Aghajanian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.